Postherpetic Neuralgia
📧 Sign up to get email alerts when something new happens for Postherpetic Neuralgia.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2022-07-18FDA Approved: PREGABALIN — Original Application (MARKSANS PHARMA LIMITED)
FDA approved the original ANDA for pregabalin from Marksans Pharma Limited (ANDA216197).
-
FDA approval · 2022-03-31FDA Approved: GABAPENTIN — Supplemental Application (Ascend Laboratories, LLC)
FDA approved a supplemental application for gabapentin from Ascend Laboratories, LLC.
-
FDA approval · 2022-03-22FDA Approved: PREGABALIN — Original Application (Advagen Pharma Ltd.)
FDA approved Pregabalin under an Original Application for Advagen Pharma Ltd., authorizing the generic product.
-
FDA approval · 2022-03-08FDA Approved: PREGABALIN — Original Application (Eskayef Pharmaceuticals Limited)
FDA approved Eskayef Pharmaceuticals Limited's original application for generic pregabalin (ANDA212988).
-
FDA approval · 2022-02-18FDA Approved: PREGABALIN — Original Application (Patrin Pharma, Inc.)
FDA approved an original application for pregabalin from Patrin Pharma, making a generic version available. This marks the approval of a gen…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2021-10-15FDA Approved: GABAPENTIN — Supplemental Application (QUALLENT PHARMACEUTICALS HEALTH LLC)
FDA approved a supplemental application for gabapentin from Quallent Pharmaceuticals Health LLC, resulting in the approval of their generic …
-
FDA approval · 2021-10-01FDA Approved: GABAPENTIN — Original Application (XLCare Pharmaceuticals, Inc.)
FDA approved the original ANDA for gabapentin from XLCare Pharmaceuticals, enabling a generic version of the anticonvulsant.
-
FDA approval · 2021-09-29FDA Approved: AMITRIPTYLINE HYDROCHLORIDE — Supplemental Application (AiPing Pharmaceutical, Inc.)
FDA approved a supplemental application for Amitriptyline Hydrochloride, a generic product submitted by AiPing Pharmaceutical, Inc., under t…
-
FDA approval · 2021-09-16FDA Approved: GRALISE — Supplemental Application (Almatica Pharma LLC)
FDA approves a supplemental application for Gralise (gabapentin) submitted by Almatica Pharma LLC.
-
FDA approval · 2021-08-05FDA Approved: QUTENZA — Supplemental Application (Averitas Pharma Inc)
FDA approved a supplemental application for QUTENZA (capsaicin) from Averitas Pharma Inc.
-
CLINICAL_TRIALS trial_result · 2021-08-05Clinical Trial Update: A Study To Compare Pregabalin/PF-00489791 Combination Versus Pregabalin Alone In Post-Herpetic Neuralgia [Phase 2]
Phase 2 trial comparing pregabalin plus PF-00489791 versus pregabalin alone in postherpetic neuralgia has completed with results posted.
-
FDA approval · 2021-07-15FDA Approved: PREGABALIN — Original Application (Tris Pharma Inc)
The FDA approved Tris Pharma's original Abbreviated New Drug Application for pregabalin, allowing a generic pregabalin product to enter the …
-
CLINICAL_TRIALS trial_result · 2021-05-28Clinical Trial Update: RN624 For Pain Of Post-Herpetic Neuralgia [Phase 2]
Phase 2 trial update for RN624 in postherpetic neuralgia has completed with results posted.
-
FDA approval · 2021-05-10FDA Approved: GABAPENTIN — Original Application (Camber Pharmaceuticals, Inc.)
FDA approved Camber Pharmaceuticals' generic gabapentin under an Original Application (ANDA 214956); the product is indicated for partial se…
-
CLINICAL_TRIALS trial_result · 2021-05-05Clinical Trial Update: Efficacy Study of Botox to Treat Neuropathic Pain [Phase 4]
A Phase 4 clinical trial update evaluating the efficacy of Botox for postherpetic neuralgia and nerve trauma has completed.
-
FDA approval · 2021-04-26FDA Approved: GABAPENTIN — Supplemental Application (Actavis Pharma, Inc.)
FDA approved a supplemental application for Gabapentin from Actavis Pharma, Inc., enabling the generic product to reach the market.
-
CLINICAL_TRIALS trial_result · 2021-04-23Clinical Trial Update: Oral LAT8881 in Neuropathic Pain [Phase 2]
Phase 2 clinical trial update for oral LAT8881 in neuropathic pain conditions has been completed with results posted.
-
FDA approval · 2021-04-13FDA Approved: PREGABALIN — Original Application (Novadoz Pharmaceuticals LLC)
FDA approves the original abbreviated new drug application for pregabalin from Novadoz Pharmaceuticals LLC, enabling a generic version of pr…
-
FDA approval · 2021-03-05FDA Approved: GABAPENTIN — Supplemental Application (Granules Pharmaceuticals Inc)
FDA approved Granules Pharmaceuticals Inc's supplemental application for gabapentin granules, approving a new granulated formulation of a ge…
-
CLINICAL_TRIALS trial_result · 2021-01-25Clinical Trial Update: A Study of the Efficacy and Safety of Pregabalin for the Treatment of Diabetic Peripheral Neuropathy or Postherpetic Neuralgia [Phase 4]
Phase 4 trial update evaluating the efficacy and safety of pregabalin for Painful Diabetic Neuropathy and Postherpetic Neuralgia; study comp…
-
FDA approval · 2020-12-16FDA Approved: NEURONTIN — Supplemental Application (Parke-Davis Div of Pfizer Inc)
FDA approved a supplemental application for Neurontin (gabapentin) submitted by Parke-Davis Div of Pfizer Inc. The action pertains to labeli…
-
FDA approval · 2020-12-16FDA Approved: NEURONTIN — Supplemental Application (Parke-Davis Div of Pfizer Inc)
The FDA approved a supplemental application for Neurontin (gabapentin) submitted by Parke-Davis Division of Pfizer Inc, indicating a change …
-
CLINICAL_TRIALS trial_result · 2020-12-11Clinical Trial Update: The Study on the Esketamine in the Treatment of Postherpetic Neuralgia [Phase 4]
A Phase 4 clinical trial update on esketamine for postherpetic neuralgia is ongoing with unknown status.
-
FDA approval · 2020-10-27FDA Approved: GABAPENTIN — Supplemental Application (BluePoint Laboratories)
The FDA approved a supplemental application for gabapentin from BluePoint Laboratories under an ANDA.
-
FDA approval · 2020-10-19FDA Approved: GABAPENTIN — Supplemental Application (QUALLENT PHARMACEUTICALS HEALTH LLC)
FDA approved a supplemental application for gabapentin from Quallent Pharmaceuticals Health LLC. The approval may modify labeling or indicat…